Investigational Drug Information for MEDI4736
✉ Email this page to a colleague
▶ Start for $1
Remove trial restrictions
What is the development status for investigational drug MEDI4736?
MEDI4736 is an investigational drug.
There have been 367 clinical trials for MEDI4736.
The most recent clinical trial was a Phase 3 trial, which was initiated on September 5th 2019.
The most common disease conditions in clinical trials are Lung Neoplasms, Carcinoma, Non-Small-Cell Lung, and Carcinoma. The leading clinical trial sponsors are AstraZeneca, MedImmune LLC, and National Cancer Institute (NCI).
There are forty-five US patents protecting this investigational drug and one international patent.
Summary for MEDI4736
| US Patents | 45 |
| International Patents | 1,063 |
| US Patent Applications | 0 |
| WIPO Patent Applications | 0 |
| Japanese Patent Applications | 0 |
| Clinical Trial Progress | Phase 3 (2019-09-05) |
| Vendors | 0 |
Recent Clinical Trials for MEDI4736
| Title | Sponsor | Phase |
|---|---|---|
| A Phase II Study Assessing the Efficacy of Etoposide Free Chemotherapy Plus Durvalumab (MEDI4736) in First Line Extensive Disease Small Cell Lung Cancer (SCLC) | Intergroupe Francophone de Cancerologie Thoracique | Phase 2 |
| Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-small Cell Lung Cancer | National Cancer Institute (NCI) | Phase 3 |
| Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-small Cell Lung Cancer | NRG Oncology | Phase 3 |
Clinical Trial Summary for MEDI4736
Top disease conditions for MEDI4736
Top clinical trial sponsors for MEDI4736
US Patents for MEDI4736
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| MEDI4736 | ⤷ Try a Trial | Synergistic combination of immunologic inhibitors for the treatment of cancer | The University of Chicago (Chicago, IL) | ⤷ Try a Trial |
| MEDI4736 | ⤷ Try a Trial | Methods of treatment with antagonists against PD-1 and PD-L1 in combination with radiation therapy | MedImmune Limited (Cambridge, GB) | ⤷ Try a Trial |
| MEDI4736 | ⤷ Try a Trial | Heterocyclic modulators of lipid synthesis | 3-V Biosciences, Inc. (Menlo Park, CA) | ⤷ Try a Trial |
| MEDI4736 | ⤷ Try a Trial | Imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer | AstraZeneca AB (Sodertalje, SE) | ⤷ Try a Trial |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for MEDI4736
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| MEDI4736 | Canada | CA2889182 | 2032-10-26 | ⤷ Try a Trial |
| MEDI4736 | European Patent Office | EP2911669 | 2032-10-26 | ⤷ Try a Trial |
| MEDI4736 | World Intellectual Property Organization (WIPO) | WO2014066834 | 2032-10-26 | ⤷ Try a Trial |
| MEDI4736 | Australia | AU2015276173 | 2034-06-17 | ⤷ Try a Trial |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
